These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 32675658

  • 21. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
    Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK.
    Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
    [Abstract] [Full Text] [Related]

  • 22. Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications.
    Sun J, Li J, Tian Z, Zhang C, Xia R, He Y.
    J Oral Pathol Med; 2022 Sep; 51(8):721-729. PubMed ID: 36087274
    [Abstract] [Full Text] [Related]

  • 23. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
    Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M.
    Hum Pathol; 2015 Jan; 46(1):94-103. PubMed ID: 25456394
    [Abstract] [Full Text] [Related]

  • 24. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
    Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, Kaanders JHAM, Groenen PJTA, Flucke UE, van Herpen CML.
    Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
    [Abstract] [Full Text] [Related]

  • 25. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP, Jo VY, Hornick JL.
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [Abstract] [Full Text] [Related]

  • 26. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.
    Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, Michael Tuttle R, Fagin JA, Klimstra DS, Katabi N, Ghossein RA.
    Mod Pathol; 2016 Sep; 29(9):985-95. PubMed ID: 27282352
    [Abstract] [Full Text] [Related]

  • 27. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.
    Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I.
    Am J Surg Pathol; 2012 Jan; 36(1):27-34. PubMed ID: 21989350
    [Abstract] [Full Text] [Related]

  • 28. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B, Haroon Al Rasheed MR, Antonescu CR, Alex D, Frosina D, Ghossein R, Jungbluth AA, Katabi N.
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [Abstract] [Full Text] [Related]

  • 29. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes.
    Skálová A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RH, Hauer L, Andrle P, Hosticka L, Branžovský J, Michal M.
    Am J Surg Pathol; 2014 Jan; 38(1):23-33. PubMed ID: 24145651
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach.
    Fisch AS, Laklouk I, Nakaguro M, Nosé V, Wirth LJ, Deschler DG, Faquin WC, Dias-Santagata D, Sadow PM.
    Hum Pathol; 2021 Aug; 114():74-89. PubMed ID: 33991527
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Clinicopathologic features of mammary analogue secretory carcinoma of salivary glands].
    Zhang XP, Ni H, Wang X, Chen H, Shi SS, Yu B, Zhou XJ, Rao Q.
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan 08; 46(1):34-37. PubMed ID: 28072974
    [Abstract] [Full Text] [Related]

  • 35. Secretory Carcinoma of the Salivary Gland: A Rarity in Children.
    Kelly GA, Venkatramani R, Quintanilla NM, Chelius DC, Roy A, Mahajan P.
    J Pediatr Hematol Oncol; 2022 May 01; 44(4):167-172. PubMed ID: 34486543
    [Abstract] [Full Text] [Related]

  • 36. Secretory carcinoma of the sinonasal cavity and pharynx: A retrospective analysis of four cases and literature review.
    Yue C, Zhao X, Ma D, Piao Y.
    Ann Diagn Pathol; 2022 Dec 01; 61():152052. PubMed ID: 36270241
    [Abstract] [Full Text] [Related]

  • 37. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F, Greim R, Krebs K, Luebben F, Dimmler A.
    Diagn Pathol; 2021 Aug 09; 16(1):73. PubMed ID: 34372873
    [Abstract] [Full Text] [Related]

  • 38. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
    Bishop JA, Yonescu R, Batista D, Begum S, Eisele DW, Westra WH.
    Hum Pathol; 2013 Oct 09; 44(10):1982-8. PubMed ID: 23773480
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic utility of phosphorylated signal transducer and activator of transcription 5 immunostaining in the diagnosis of mammary analogue secretory carcinoma of the salivary gland: A comparative study of salivary gland cancers.
    Kawahara A, Taira T, Abe H, Takase Y, Kurita T, Sadashima E, Hattori S, Imamura I, Matsumoto S, Fujisaki H, Sueyoshi K, Akiba J, Kage M.
    Cancer Cytopathol; 2015 Oct 09; 123(10):603-11. PubMed ID: 26252941
    [Abstract] [Full Text] [Related]

  • 40. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.
    Ann Oncol; 2016 May 09; 27(5):920-6. PubMed ID: 26884591
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.